The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the risk of serious kidney injury that can result from dehydration. This comes after people taking the medication for either obesity or diabetes have needed to undergo…| New Atlas
A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy – without adding side effects – in a mid-stage clinical trial, pointing to a powerful new combination approach to tackling obesity.| New Atlas
Is obesity a disease or a risk factor for disease? In medical circles – and outside of them – the question is contentious, with supporters on either side. In a newly published report, the Global Commission on Clinical Obesity has strived to settle the debate, introducing a new framework that…| New Atlas
It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting impressive results following a large, robust 72-week trial that saw obese participants lose an average of 27.3 lb, or 12.4% of their body weight with the once-daily pill.| New Atlas
In a world where slimness is often equated with health, a new Danish study has flipped the narrative: being slightly overweight, or even mildly obese, may not be as deadly as once thought. In fact, in some ways it could be safer than being thin.| New Atlas
